CPMG Inc

Q1 2018 13F Holdings Report, Restatement, Options Holdings

Signature - Title
John E. Bateman - Chief Operating Officer
Location
Dallas, TX
Options holdings as of
March 31, 2018
Notional value $
$752M
Number of holdings
3
Date filed
10/2/2018, 04:17 PM
Description
All US holdings of this investor are reported in this report.
Previous filing
Q4 2017 - Oct 2, 2018
Next filing
Q2 2018 - Oct 2, 2018
Stock holdings
Showing options holdings, see here for stock holdings
Sym Company Class Option Share Change Activity * Price $ Shares Notional Value
Filing 2018 Q1 - Restatement compared to 2017 Q4 - Restatement by default.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
John E. Bateman Chief Operating Officer Dallas, Texas 10/2/2018

This Amendment Number 1 is being filed to restate the position information in Reata Pharmaceuticals, Inc. ("Reata"). The Form 13F-HR filed on May 15, 2018 inadvertently reported the position information for Reata as the total of Class A and Class B shares over which CPMG, Inc. ("CPMG") had investment discretion as of March 31, 2018. This Amendment Number 1 includes only the reportable 2,912,523 Class A shares over which CPMG had investment discretion as of March 31, 2018. This Amendment Number 1 does not include the 1,692,857 Class B shares of Reata over which CPMG had investment discretion as of March 31, 2018 because such Class B shares were not included in the relevant quarter's Official List of Section 13(f) Securities, and thus should be excluded.